MedTrace Logo

Integrated Radiographic and Metabolomics Risk Assessment in Patients With Interstitial Lung Diseases

NCT04119115 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 28

Last updated 2023-05-03

No results posted yet for this study

Summary

The purpose of this study is to find out if combining a state-of-the-art form imaging modality with metabolomics in different types of Interstitial Lung Diseases (ILD) patients compared to controls with chronic obstructive pulmonary disorder (COPD)/emphysema and healthy controls will be a better predictor of disease progression. ILD's are a group of chronic, progressive lung diseases. The most common ILD is idiopathic pulmonary fibrosis (IPF). Metabolomics provides a "snapshot" in time of all metabolites present in a biological sample. The imaging procedure should take approximately 20 minutes. All study related collections of samples will be done in a single visit if possible. There are no direct benefits to participants. This is not a treatment study.

Conditions

Interventions

DEVICE

CT-V

CT-V is a newer computed tomography scan which is more comprehensive and tracks movement of the lungs.

OTHER

Metabolites

Metabolites are compounds which can be measured in biospecimens and may indicate a disease or biological process.

Sponsors & Collaborators

  • William Beaumont Hospitals

    lead OTHER

Principal Investigators

  • Girish B Nair, MD · William Beaumont Hospitals

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-09-30
Primary Completion
2022-10-20
Completion
2022-10-20

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04119115 on ClinicalTrials.gov